Baird analyst David Rescott lowered the firm’s price target on Merit Medical (MMSI) to $83 from $92 and keeps an Outperform rating on the shares. The firm updated its model following encouraging upside Q1 results nut where theback-end growth ramp likeely weighs on the shares until the second half of the year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target lowered to $77 from $95 at JPMorgan
- Merit Medical price target lowered to $90 from $101 at Needham
- Merit Medical price target lowered to $83 from $101 at Raymond James
- Merit Medical price target lowered to $80 from $100 at BofA
- Analyst Reiterates Buy on Merit Medical Systems as Strong Q1 Results and Cash Generation Offset Growth Deceleration, Trims Price Target to $90 on Sector Multiple Compression